Hematol Malign News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Hematol Malign. Real-time updates on events, politics, business and more.

GSK : Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia -September 15, 2023 at 04:42 pm EDT

September 15, 2023

Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop...

United States Nina Mojas Kapila Viges Ann Hematol Rubena Mesa Drug Administration

Source: marketscreener.com

GSK regulatory submission for momelotinib accepted for review in Japan

September 11, 2023

GSK regulatory submission for momelotinib accepted for review in Japan

United States Mascarenhasj Myelofibrosis National Library Of Medicine Research Foundation American Society Of Clinical Oncology National Organization For Rare Disorders

Source: directorstalkinterviews.com

GSK : regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator - Form 6-K -Today at 08:51 am

September 11, 2023

GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator ● Regulatory submission included data from pivotal...

United Kingdom General United Kingdom City Of United States Sarah Clements Jeff Mclaughlin

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Hematol Malign News Today

GSK : Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia -September 15, 2023 at 04:42 pm EDT

GSK regulatory submission for momelotinib accepted for review in Japan

GSK : regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator - Form 6-K -Today at 08:51 am

Explore More Categories